Most people's understanding of Zhong Shanshan (read the third sound) stays in a spring. In the history of commercial services after China's reform, the rotation of the rich basically followed the rapid development and changes of China's industry. For example, in the early stage, there were Shanxi coal bosses, then there were Chen Tianqiao and Ma Hua Teng who played games, and Ma Yun who did e-commerce and countless real estate tycoons.
Now, it's Zhong Shanshan's turn to make a fortune. In fact, Zhong Shanshan has multiple identities, one is mineral water first, and the other is king of vaccines. Zhong Shanshan Group has two listed companies, one is Chuntian with a total market value of 470 billion, and the other is Wan Tai Bio with a total market value of 654.38+0668 billion. Today, the battalion chief wants to tell you about Wan Tai Bio, the first biopharmaceutical company in China to develop HPV vaccine.
Human Papillomavirus (HPV) is a key viral infection that causes breast cancer, rectal cancer, vaginal cancer, anal cancer's disease and its penile cancer. Moreover, like COVID-19, human papillomavirus infection has evolved into models and specifications above 1 10, among which 14 models and specifications can immediately cause other tumors such as breast cancer.
Rectal cancer ranks first in the prevalence rate of Ms. China, and it is the most harmful cancer disease to Ms. China's life. However, HPV vaccine can effectively prevent various cancer diseases caused by human papillomavirus infection and build a protective wall for women's health.
The first company in the world to scientifically develop HPV vaccine is Merck of the United States. As early as 2006, Merck successfully developed the world's first tetravalent HPV vaccine. Following Merck, the British company Glenstock developed a bivalent HPV vaccine in 2007. By 20 14, Merck of the United States further developed a nine-valent HPV vaccine.
So, what is the difference between bivalent, tetravalent and nonavalent human papillomavirus vaccines? In the original article, the captain said that human papillomavirus infection has evolved and separated many kinds of papillomavirus 1 10, and the nine-valent HPV vaccine can defend against more than 90% of rectal cancer, and can resist the human papillomavirus infection of most papillomaviruses. The tetravalent HPV vaccine can resist the virus infection of HPV6, 1 1, 16 and 18, while the bivalent HPV vaccine can only resist the virus infection of 16/ 18.
In other words, the nine-valent HPV vaccine is the most defensive vaccine, followed by the four-valent HPV vaccine, but at this stage these two kinds of HPV vaccines are monopolized by Merck of the United States. However, bivalent HPV vaccine is also critical. Because there is an age limit for nine-valent HPV vaccine injection, women must be injected before the age of 26, while bivalent HPV vaccine is suitable for women aged 9-45 and has a more general group base. At the same time, 70% of rectal cancer is basically caused by 16/ 18 human papillomavirus. Therefore, bivalent HPV vaccine is the most popular in maintenance and coverage.
As we all know, Glenstock Company in Britain developed bivalent HPV vaccine as early as 2007. It was not until 20 19 that bivalent HPV vaccine was developed, and it was approved to be marketed in China in 2020.
Wan Tai Bio, which is controlled by Zhong Shanshan, happens to be the first microbial producer in China to develop bivalent HPV vaccine in China. It is not easy to develop bivalent HPV vaccine in China. Zhong Shanshan and Wan Tai started the project in 2003, and it took19 years to start development, which took 16 years. It can be said that a hot sale in spring has given HPV vaccine research and development relatively stable self-owned funds.
Behind the domestic HPV vaccine is Xiamen University. Wan Tai Bio * * * owns 189 domestic and international patent inventions, of which 140 patents are all owned by Xiamen University. The connection between the two is also very simple. Zhong Shanshan pays, Xiamen University produces outstanding talents, and the patented inventions are owned by both parties. However, Zhong Shanshan, as the biological controller of Wan Tai, has become a big beneficiary of HPV vaccine.
Successful production and manufacture of HPV vaccine in China has obvious benefits. The imported bivalent HPV vaccine produced by GlaxoSmithKline requires 580 yuan for one shot, and three shots are injected in the whole process, and the cost is 1.740 yuan. At such a high price, bivalent HPV vaccine can't be popularized nationwide free of charge on the Internet from beginning to end, and China's medical insurance fund can't be under pressure.
However, after it was made in Wan Tai, the price was immediately 329 yuan per needle, which was divided into two embroidery methods and three needle methods, and the prices were 658 yuan and 987 yuan respectively. Compared with the imported bivalent HPV vaccine, the price of the HPV vaccine produced by Wan Tai has dropped to 1/3 or 1/2.
Once the biological HPV vaccine in Wan Tai is released, there will be a high demand. In April 2020, Wan Tai Bio landed in the A-share market. In just two years, the stock price soared from 8 yuan to 274 yuan, and the highest was 299 yuan, an increase of 34 times. The market value of Zhong Shanshan has also soared.
In 20021year, Wan Tai Bio sold only one HPV vaccine for 3 billion yuan, with a profit rate of 90%. However, it is Merck of the United States that makes more money than Wan Tai Biotech. In 20021year, Mercer East China's total revenue exceeded 4.2 billion US dollars, equivalent to 267 billion yuan. But what's more grandiose is that zhifei Bio only relies on Merck's HPV vaccine, and its operating income is higher than Merck's China, with an annual operating income of over 30 billion in 2002/kloc-0!
This is because, up to now, Merck is still the only biopharmaceutical company in the world that can produce tetravalent and nonavalent human papillomavirus vaccines. One dose of nine-valent HPV vaccine 1298 yuan, three doses of 3894 yuan. In fact, due to the large demand for nine-valent HPV vaccine, the total price on the market has exceeded 6,000 yuan, with an average of more than 2,000 yuan per needle. At this time, most women can't book yet, and they have to wait in line for at least half a year or even more.
HPV vaccine is like a gold mine, but any enterprise that can understand its production technology has obtained the exploration right. From the perspective of national health, Guangdong Province, China has gradually formulated a plan to inject bivalent HPV vaccine for beautiful girls in junior high schools completely free of charge. Captain predicts that free injections will be popularized for beautiful girls in junior high schools nationwide in the future, and Wan Tai Biology will benefit from it in the medium and long term.
The good news is that in March 2022, Watsons Bio announced the successful development of bivalent HPV vaccine, becoming the second HPV vaccine manufacturer in China and the fourth in the world. With watson biological as a competitor, under the current national centralized procurement policy, it is estimated that the price of HPV vaccine will further decrease.
However, Zhong Shanshan's Wan Tai Biological Company has gone further in the research and development of the nine-valent HPV vaccine and entered the third stage of clinical research. Wan Tai Bio is likely to become the first biopharmaceutical company in China to get rid of Merck's monopoly on nine-valent HPV vaccine.
Zhong Shanshan's wealth value may soar again in two or three years. Zhong Shanshan sells water in one hand and vaccines in the other. As long as there are some people, they need to drink water. As long as there are women, you need to get HPV vaccine. At the same time, Zhong Shanshan has entered two long-standing golden tracks, which are almost inexhaustible. Zhong Shanshan is not only a loader in nature, but also a gold digger with the title of "the first vaccine"!